(Q39335373)

11 September 2017

title

Cancer-testis antigen BORIS is a novel prognostic marker for patients with esophageal cancer (English)

1 reference

11 September 2017

Koji Okabayashi

1

1 reference

11 September 2017

Tomonobu Fujita

2

1 reference

11 September 2017

Junichiro Miyazaki

3

1 reference

11 September 2017

Tsutomu Okada

4

1 reference

11 September 2017

Takashi Iwata

5

1 reference

11 September 2017

Nobumaru Hirao

6

1 reference

11 September 2017

Shinobu Noji

7

1 reference

11 September 2017

Nobuo Tsukamoto

8

1 reference

11 September 2017

Naoki Goshima

9

1 reference

11 September 2017

Hirotoshi Hasegawa

10

1 reference

11 September 2017

Hiroya Takeuchi

11

1 reference

11 September 2017

Masakazu Ueda

12

1 reference

11 September 2017

Yuko Kitagawa

13

1 reference

11 September 2017

Yutaka Kawakami

14

1 reference

11 September 2017

publication date

16 July 2012

1 reference

11 September 2017

1 reference

11 September 2017

volume

103

1 reference

11 September 2017

issue

9

1 reference

11 September 2017

page(s)

1617-1624

1 reference

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02355.X

Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02355.X

A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02355.X

An oncological view on the blood-testis barrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02355.X

Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02355.X

Involvement of epithelial cell transforming sequence-2 oncoantigen in lung and esophageal cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02355.X

Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02355.X

Expression of D2-40 in lymphatic endothelium of normal tissues and in vascular tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02355.X

A novel cancer testis antigen that is frequently expressed in pancreatic, lung, and endometrial cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02355.X

Immune responses to DNA mismatch repair enzymes hMSH2 and hPMS1 in patients with pancreatic cancer, dermatomyositis and polymyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02355.X

Aberrant expression of homeobox gene HOXA7 is associated with müllerian-like differentiation of epithelial ovarian tumors and the generation of a specific autologous antibody response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02355.X

Human protein factory for converting the transcriptome into an in vitro-expressed proteome,.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02355.X

BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02355.X

A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02355.X

Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02355.X

Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02355.X

Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02355.X

BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed in breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02355.X

Global expression analysis of cancer/testis genes in uterine cancers reveals a high incidence of BORIS expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02355.X

Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02355.X

The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02355.X

Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02355.X

Dynamic transcriptional regulatory complexes including BORIS, CTCF and Sp1 modulate NY-ESO-1 expression in lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02355.X

Heterogeneous expression of GAGE, NY-ESO-1, MAGE-A and SSX proteins in esophageal cancer: Implications for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02355.X

NY-ESO-1 expression and immunogenicity in esophageal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02355.X

NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02355.X

Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02355.X

CTCFL/BORIS is a methylation-independent DNA-binding protein that preferentially binds to the paternal H19 differentially methylated region

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02355.X

An imprinting element from the mouse H19 locus functions as a silencer in Drosophila.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02355.X

Transgenic RNAi reveals essential function for CTCF in H19 gene imprinting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02355.X

CTCF binding at the H19 imprinting control region mediates maternally inherited higher-order chromatin conformation to restrict enhancer access to Igf2

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02355.X

The H19 non-coding RNA is essential for human tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02355.X

Risk factors of lymph node metastasis in T1 esophageal squamous cell carcinoma

21 January 2018

1 reference

12 December 2020

LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer.

1 reference

12 December 2020

Loss of H19 imprinting in esophageal cancer

1 reference

12 December 2020

Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells

1 reference

12 December 2020

Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes

1 reference

12 December 2020

Loss of imprinting of IGF2 and H19 in osteosarcoma is accompanied by reciprocal methylation changes of a CTCF-binding site

1 reference

12 December 2020

A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors

1 reference

12 December 2020

Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years

1 reference

12 December 2020

DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer

1 reference

12 December 2020

CD4+ and CD8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma

1 reference

12 December 2020

T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein.

1 reference

12 December 2020

Identification of the HERV-K gag antigen in prostate cancer by SEREX using autologous patient serum and its immunogenicity

1 reference

12 December 2020

10.1111/J.1349-7006.2012.02355.X

Identifiers

DOI

1 reference

11 September 2017

0 references

1 reference